These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 15998902)

  • 1. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
    Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
    Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
    Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
    Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
    Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
    Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
    Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
    Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
    Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
    J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
    Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Pentsova EI; Mellinghoff IK; Nolan C; Gavrilovic I; DeAngelis LM; Abrey LE; Holland EC; Omuro A; Lacouture ME; Ludwig E; Lassman AB
    Ann Clin Transl Neurol; 2020 Apr; 7(4):429-436. PubMed ID: 32293798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
    Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
    Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
    Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
    Sarkaria JN; Galanis E; Wu W; Dietz AB; Kaufmann TJ; Gustafson MP; Brown PD; Uhm JH; Rao RD; Doyle L; Giannini C; Jaeckle KA; Buckner JC
    Clin Cancer Res; 2010 Nov; 16(22):5573-80. PubMed ID: 20921209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.